Skip to main content

Table 3 Results of subgroup analysis exploring source of heterogeneity with OS and DFS

From: Clinicopathological and prognostic value of SIRT6 in patients with solid tumors: a meta-analysis and TCGA data review

Subgroups

OS

DFS

HR (95% CI)

I2 (P-value)

HR (95% CI)

I2 (P-value)

Location

 Nu

0.86 (0.45–1.66)

82.5% (P < 0.001)

0.62 (0.26–0.91)

88.2% (P < 0.001)

 Cy

0.30 (0.18–0.50)

0.0% (P = 1.000)

–

–

 NR

0.65 (0.38–1.13)

81.8% (P < 0.001)

0.37 (0.14–0.97)

76.5% (P = 0.014)

Region

 China

0.79 (0.51–1.23)

78.0% (P < 0.001)

0.80 (0.22–2.88)

91.9% (P < 0.001)

 Other

0.44 (0.19–1.03)

88.4% (P < 0.001)

0.32 (0.19–0.54)

41.8% (P = 0.180)

Patients number

 ≥ 100

0.56 (0.36–0.88)

80.7% (P < 0.001)

0.48 (0.26–0.91)

0.0% (P = 0.384)

 < 100

0.80 (0.39–1.65)

82.9% (P < 0.001)

0.70 (0.18–2.78)

85.7% (P = 0.001)

NOS score

 > 7

0.54 (0.27–1.07)

82.8% (P < 0.001)

0.26 (0.14–0.48)

28.3% (P = 0.237)

 ≤ 7

0.74 (0.45–1.23)

82.8% (P < 0.001)

0.48 (0.26–0.91)

87.9% (P < 0.001)

Publication year

 ≥ 2018

0.77 (0.37–1.60)

87.1% (P < 0.001)

0.40 (0.17–0.94)

88.5% (P < 0.001)

 ≤ 2017

0.59 (0.37–0.94)

78.3% (P < 0.001)

0.48 (0.26–0.91)

83.8% (P < 0.001)